NewAmsterdam Takes Another Step Toward CETP Inhibitor Success

 
• By Alaric DeArment
  
NewAmsterdam announced topline Phase II results for its cholesterol-lowering CETP inhibitor • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D